[go: up one dir, main page]

WO2003043565A3 - Methodes de diagnostic et de traitement de maladies associees a l'expression modifiee de nrf2 - Google Patents

Methodes de diagnostic et de traitement de maladies associees a l'expression modifiee de nrf2 Download PDF

Info

Publication number
WO2003043565A3
WO2003043565A3 PCT/IB2002/005830 IB0205830W WO03043565A3 WO 2003043565 A3 WO2003043565 A3 WO 2003043565A3 IB 0205830 W IB0205830 W IB 0205830W WO 03043565 A3 WO03043565 A3 WO 03043565A3
Authority
WO
WIPO (PCT)
Prior art keywords
diagnosis
treatment
nrf2
methods
diseases associated
Prior art date
Application number
PCT/IB2002/005830
Other languages
English (en)
Other versions
WO2003043565A2 (fr
Inventor
Finn Skou Pedersen
Annette Balle Soerensen
Helle Moving
Original Assignee
Univ Aarhus
Finn Skou Pedersen
Annette Balle Soerensen
Helle Moving
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/962,855 external-priority patent/US20020164576A1/en
Priority claimed from US09/962,929 external-priority patent/US20020115058A1/en
Priority claimed from US09/962,854 external-priority patent/US20030044803A1/en
Priority claimed from US09/963,131 external-priority patent/US20030224460A1/en
Application filed by Univ Aarhus, Finn Skou Pedersen, Annette Balle Soerensen, Helle Moving filed Critical Univ Aarhus
Priority to AU2002364889A priority Critical patent/AU2002364889A1/en
Publication of WO2003043565A2 publication Critical patent/WO2003043565A2/fr
Publication of WO2003043565A3 publication Critical patent/WO2003043565A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne des nouvelles séquences destinées au diagnostic et au traitement du lymphome et de la leucémie. En outre, la présente invention concerne l'utilisation de nouvelles compositions destinées à des méthodes de criblage.
PCT/IB2002/005830 2001-09-24 2002-09-24 Methodes de diagnostic et de traitement de maladies associees a l'expression modifiee de nrf2 WO2003043565A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002364889A AU2002364889A1 (en) 2001-09-24 2002-09-24 Methods for diagnosis and treatment of diseases associated with altered expression of nrf2

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US09/962,855 2001-09-24
US09/962,855 US20020164576A1 (en) 2000-09-22 2001-09-24 Methods for diagnosis and treatment of diseases associated with altered expression of Nrf2
US09/962,929 US20020115058A1 (en) 2000-09-22 2001-09-24 Methods for diagnosis and treatment of diseases associated with altered expression of Pik3r1
US09/962,854 US20030044803A1 (en) 2000-09-22 2001-09-24 Methods for diagnosis and treatment of diseases associated with altered expression of JAK1
US09/963,131 2001-09-24
US09/963,131 US20030224460A1 (en) 2000-09-22 2001-09-24 Novel compositions and methods for lymphoma and leukemia
US09/962,854 2001-09-24
US09/962,916 2001-09-24
US09/962,916 US20030077590A1 (en) 2000-09-22 2001-09-24 Methods for diagnosis and treatment of diseases associated with altered expression of neurogranin
US09/962,929 2001-09-24

Publications (2)

Publication Number Publication Date
WO2003043565A2 WO2003043565A2 (fr) 2003-05-30
WO2003043565A3 true WO2003043565A3 (fr) 2003-11-13

Family

ID=27542309

Family Applications (5)

Application Number Title Priority Date Filing Date
PCT/IB2002/004134 WO2003027276A2 (fr) 2001-09-24 2002-09-24 Nouvelles compositions et procedes relatifs aux lymphomes et aux leucemies
PCT/IB2002/004197 WO2003027295A2 (fr) 2001-09-24 2002-09-24 Procedes de diagnostic et de traitement de maladies associees a l'expression alteree de la jak1
PCT/IB2002/004158 WO2003027321A2 (fr) 2001-09-24 2002-09-24 Methodes de diagnostic et de traitement de maladies associees a une expression alteree de neurogranine
PCT/IB2002/005830 WO2003043565A2 (fr) 2001-09-24 2002-09-24 Methodes de diagnostic et de traitement de maladies associees a l'expression modifiee de nrf2
PCT/IB2002/004123 WO2003027320A2 (fr) 2001-09-24 2002-09-24 Methodes de diagnostic et de traitement de maladies associees a l'expression modifiee de pik3r1

Family Applications Before (3)

Application Number Title Priority Date Filing Date
PCT/IB2002/004134 WO2003027276A2 (fr) 2001-09-24 2002-09-24 Nouvelles compositions et procedes relatifs aux lymphomes et aux leucemies
PCT/IB2002/004197 WO2003027295A2 (fr) 2001-09-24 2002-09-24 Procedes de diagnostic et de traitement de maladies associees a l'expression alteree de la jak1
PCT/IB2002/004158 WO2003027321A2 (fr) 2001-09-24 2002-09-24 Methodes de diagnostic et de traitement de maladies associees a une expression alteree de neurogranine

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/IB2002/004123 WO2003027320A2 (fr) 2001-09-24 2002-09-24 Methodes de diagnostic et de traitement de maladies associees a l'expression modifiee de pik3r1

Country Status (2)

Country Link
AU (4) AU2002330713A1 (fr)
WO (5) WO2003027276A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006265113A1 (en) * 2005-07-01 2007-01-11 The Johns Hopkins University Compositions and methods for the treatment or prevention of disorders relating to oxidative stress
KR20090019767A (ko) * 2006-02-14 2009-02-25 더프레지던트앤드펠로우즈오브하바드칼리지 유사분열 진행 유전자 및 유사분열을 조절하는 방법
AU2020289484A1 (en) * 2019-06-07 2021-12-23 Emory University KRAS G12V mutant binds to JAK1, inhibitors, pharmaceutical compositions, and methods related thereto

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999041985A1 (fr) * 1998-02-23 1999-08-26 Quark Biotech, Inc. Secretion de facteurs inhibiteurs de croissance dependant de p53
WO1999065928A2 (fr) * 1998-06-19 1999-12-23 Genzyme Corporation Population de polynucleotides isoles de tissus mammaires tumoraux metastatiques ou non metastatiques
WO2001057189A2 (fr) * 2000-02-07 2001-08-09 Quark Biotech, Inc. Genes de la voie fas
WO2001096390A2 (fr) * 2000-06-09 2001-12-20 Corixa Corporation Compositions et procedes pour la therapie et le diagnostic du cancer du colon
WO2002020849A2 (fr) * 2000-09-08 2002-03-14 New York University Marqueurs de gene utiles pour detecter des lesions de la peau dues au rayonnement ultraviolet
WO2002020846A2 (fr) * 2000-09-08 2002-03-14 New York University Methodes de criblage pour identifier des composes modulant une reponse d'une cellule a l'exposition a un rayonnement ultraviolet
WO2002022884A2 (fr) * 2000-09-12 2002-03-21 Transgenetics Incorporated Organisation en micro-reseaux de genes cibles de facteur de transcription

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ237669A (en) * 1990-04-13 1992-08-26 Res Dev Foundation T-cell proteins expressed in t-cell development and their preparation
US5821069A (en) * 1993-06-30 1998-10-13 Ludwig Institute For Cancer Research Method for determining tyrosine kinase in a sample
US6300058B1 (en) * 1992-01-29 2001-10-09 Hitachi Chemical Research Center, Inc. Method for measuring messenger RNA
AU6407696A (en) * 1995-07-07 1997-02-10 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Method of identifying inhibitors of the jak-stat signal transduction pathway
WO1998016557A1 (fr) * 1996-10-11 1998-04-23 The General Hospital Corporation Dosages pour recepteurs lies a la proteine g
EP0877806A1 (fr) * 1996-11-01 1998-11-18 Onyx Pharmaceuticals, Inc. Sequences nucleotidiques codant des proteines associees de phosphatidylinositol-3 kinase et leurs utilisations
US5994076A (en) * 1997-05-21 1999-11-30 Clontech Laboratories, Inc. Methods of assaying differential expression
EP0988398A4 (fr) * 1997-05-21 2005-05-18 Clontech Lab Inc Ensembles d'acide nucleique
EP1053319A2 (fr) * 1998-01-28 2000-11-22 Chiron Corporation Genes humains et expression de produits genetiques ii
DE19817947A1 (de) * 1998-04-17 1999-10-28 Metagen Gesellschaft Fuer Genomforschung Mbh Menschliche Nukleinsäuresequenzen aus Myometrium-Tumorgewebe
ATE269295T1 (de) * 1998-04-17 2004-07-15 Parker Hughes Inst Btk inhibitoren und verfahren zur identifizierung und verwendung
US6100090A (en) * 1999-06-25 2000-08-08 Isis Pharmaceuticals Inc. Antisense inhibition of PI3K p85 expression
JP2002536963A (ja) * 1998-12-22 2002-11-05 ミリアド・ジェネティックス・インコーポレイテッド 神経変性疾患におけるタンパク質−タンパク質相互作用
US6110664A (en) * 1999-06-25 2000-08-29 Isis Pharmaceuticals Inc. Antisense inhibition of G-alpha-S1 expression
GB9917165D0 (en) * 1999-07-22 1999-09-22 Knoll Ag Polypeptides polynuclcotides and uses thereof
AU779908B2 (en) * 1999-09-10 2005-02-17 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2001030973A2 (fr) * 1999-10-25 2001-05-03 Princeton University Sequences genetiques associees a la proliferation et aux pathologies des cellules neuronales
AU1760201A (en) * 1999-11-12 2001-06-06 Fred Hutchinson Cancer Research Center Methods for treatment of human huntington's disease and methods of screening foractive agents
EP1250456A2 (fr) * 2000-01-07 2002-10-23 Curagen Corporation Acides nucleiques renfermant des polymorphismes de nucleotide simple et procede d'utilisation associe
CA2406278C (fr) * 2000-04-25 2012-06-05 Icos Corporation Inhibiteurs de la phosphatidyl-inositol 3-kinase delta humaine
DE60112272T2 (de) * 2000-04-27 2006-05-24 Astellas Pharma Inc. Imidazopyridin-derivate
EP1354062A2 (fr) * 2000-09-13 2003-10-22 Archemix Corporation Biocapteur d'acide nucleique active par une cible et ses procedes d'utilisation
AU2002236533A1 (en) * 2000-11-20 2002-05-27 Isis Pharmaceuticals, Inc. Antisense modulation of pi3k p85 expression
WO2002059367A2 (fr) * 2000-11-30 2002-08-01 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Jeu de microechantillons de diagnostic pour ibd, maladie de crohn et colite ulcereuse
AUPR279101A0 (en) * 2001-01-30 2001-02-22 Cytopia Pty Ltd Protein kinase signalling
EP1363702A4 (fr) * 2001-01-30 2007-08-22 Cytopia Pty Ltd Procedes d'inhibition de kinases
WO2002070742A1 (fr) * 2001-03-01 2002-09-12 Epigenomics Ag Procede de mise au point de groupes d'echantillons de genes a des fins de diagnostic et de therapie qui sont bases sur l'expression et l'etat de methylation des genes
CA2459219A1 (fr) * 2001-09-17 2003-03-27 Protein Design Labs, Inc. Procedes de diagnostic du cancer, compositions et procedes de criblage de modulateurs du cancer
GB0122914D0 (en) * 2001-09-22 2001-11-14 Univ Nottingham Modulation of stat activity

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999041985A1 (fr) * 1998-02-23 1999-08-26 Quark Biotech, Inc. Secretion de facteurs inhibiteurs de croissance dependant de p53
WO1999065928A2 (fr) * 1998-06-19 1999-12-23 Genzyme Corporation Population de polynucleotides isoles de tissus mammaires tumoraux metastatiques ou non metastatiques
WO2001057189A2 (fr) * 2000-02-07 2001-08-09 Quark Biotech, Inc. Genes de la voie fas
WO2001096390A2 (fr) * 2000-06-09 2001-12-20 Corixa Corporation Compositions et procedes pour la therapie et le diagnostic du cancer du colon
WO2002020849A2 (fr) * 2000-09-08 2002-03-14 New York University Marqueurs de gene utiles pour detecter des lesions de la peau dues au rayonnement ultraviolet
WO2002020846A2 (fr) * 2000-09-08 2002-03-14 New York University Methodes de criblage pour identifier des composes modulant une reponse d'une cellule a l'exposition a un rayonnement ultraviolet
WO2002022884A2 (fr) * 2000-09-12 2002-03-21 Transgenetics Incorporated Organisation en micro-reseaux de genes cibles de facteur de transcription

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ALIZADEH A A ET AL: "DISTINCT TYPES OF DIFFUSE LARGE B-CELL LYMPHOMA IDENTIFIED BY GENE EXPRESSION PROFILING", NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 403, 3 February 2000 (2000-02-03), pages 503 - 512, XP002943414, ISSN: 0028-0836 *
BLOOD, vol. 94, no. 10 SUPPL. 1 PART 2, 15 November 1999 (1999-11-15), Forty-first Annual Meeting of the American Society of Hematology;New Orleans, Louisiana, USA; December 3-7, 1999, pages 140b, ISSN: 0006-4971 *
CHAN KAIMIN ET AL: "NRF2, a member of the NFE2 family of transcription factors, is not essential for murine erythropoiesis, growth, and development.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 93, no. 24, 1996, 1996, pages 13943 - 13948, XP002251107, ISSN: 0027-8424 *
CHENAIS BENOIT: "Requirement of GATA-1 and p45 NF-E2 expression in butyric acid-induced erythroid differentiation.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 253, no. 3, 30 December 1998 (1998-12-30), pages 883 - 886, XP002251109, ISSN: 0006-291X *
CHUI DAVID H K ET AL: "CDNA cloning of murine Nrf 2 gene, coding for a p45 NF-E2 related transcription factor.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 209, no. 1, 1995, pages 40 - 46, XP002934232, ISSN: 0006-291X *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 15 November 1999 (1999-11-15), LEHNHARDT ANJA ET AL: "Expression of fNF-E2 mRNA, but not aNF-E2-mRNA correlates with GATA-1 mRNA and NF-E2 p45 protein expression in leukemic cell lines and in primary cells.", XP002251108, Database accession no. PREV200000046601 *
MOI P ET AL: "Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the beta-globin locus control region.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 91, no. 21, 1994, 1994, pages 9926 - 9930, XP002964572, ISSN: 0027-8424 *
RAMOS-GOMEZ M ET AL: "Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 13 MAR 2001 UNITED STATES, vol. 98, no. 6, 13 March 2001 (2001-03-13), pages 3410 - 3415, XP002251110, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
AU2002330713A1 (en) 2003-04-07
WO2003027295A3 (fr) 2003-10-16
AU2002337442A1 (en) 2003-04-07
WO2003027320A2 (fr) 2003-04-03
AU2002364889A8 (en) 2003-06-10
WO2003027321A2 (fr) 2003-04-03
WO2003027295A2 (fr) 2003-04-03
WO2003043565A2 (fr) 2003-05-30
WO2003027276A3 (fr) 2004-02-12
WO2003027321A3 (fr) 2003-11-06
AU2002329000A1 (en) 2003-04-07
WO2003027276A2 (fr) 2003-04-03
WO2003027320A3 (fr) 2003-10-23
AU2002364889A1 (en) 2003-06-10

Similar Documents

Publication Publication Date Title
WO2003008583A3 (fr) Nouvelles compositions et methodes relatives au cancer
EP2014669A3 (fr) Procédés et compositions de lutte contre le cancer
WO2004006858A3 (fr) Composes, compositions et methodes d'utilisation de ces derniers
EP2497478A3 (fr) Composition d'oligosaccarides et leur utilisation dans le traitement d'infection
WO2003045230A3 (fr) Compositions et procedes contre le cancer
WO2003000200A3 (fr) ss-2'-OU 3'-HALONUCLEOSIDES
WO2005027966A3 (fr) Anticorps aux fonctions d'effecteur modifiees
WO2003066661A3 (fr) Anticorps humains du dr4 et utilisations
TW200509892A (en) Novel aminobenzophenone compounds
ZA200409492B (en) Compositions and methods for the diagnosis and treatment of tumor.
GB0111186D0 (en) Novel compounds
AU2003300368A1 (en) Methods and compositions for the diagnosis, prognosis, and treatment of cancer
WO2001017543A3 (fr) Compositions et procedes permettant la prevention ou le traitement du cancer et de la perte osseuse associee au cancer
WO2000066528A3 (fr) Novel quinones utilisees dans le traitements de maladies
WO2003057146A3 (fr) Compositions et procedes concernant le cancer
WO2005051288A3 (fr) Compositions apportant des benefices a la peau a l'aide d'intermediaires metaboliques cellulaires cle
WO2001079164A3 (fr) Dithiocarbamates n-substitues utilises dans le traitement de troubles biologiques
WO2002081745A3 (fr) Genes impliques dans l'osteogenese et procedes d'utilisation associes
WO2004099388A3 (fr) Complexes de polypeptides cbl-b et methodes associees
WO2003053224A3 (fr) Nouvelles compositions et methodes contre le cancer
IL175369A0 (en) Novel compound, corresponding compositions, preparation and/or treatment methods
WO2003045324A3 (fr) 14-methyl-epothilones
WO2002024867A3 (fr) Nouvelles compositions et nouvelles methodes pour le diagnostic et le traitement des lymphomes et des leucemies
WO2005010165A3 (fr) Alpha-fetoproteine humaine non-glycosylee, procedes de production et utilisations de celle-ci
WO2003035837A3 (fr) Nouvelles compositions et procedes relatifs au cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP